Skip to content
value.today

OncoMed Pharmaceuticals Inc

Total raised
$22 M
1 round on record
Latest round
$22 M
Dec 2013
First round on record
Dec 2013
Today
Private
See the company page

OncoMed Pharmaceuticals Inc is listed today as OncoMed: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of OncoMed Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2013$22 MNo. 1$10 to $50 million

OncoMed Pharmaceuticals Inc: Raise no. 1, Dec 2013

Investors in this round

1 investor had bought by the notice of Dec 6, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 21 investors are named for OncoMed Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alicia J. Hager · Executive Officer
  • Austin J. Gurney · Executive Officer
  • Jakob A. Dupont · Executive Officer
  • John A. Lewicki · Executive Officer
  • Paul J. Hastings · Executive Officer, Director
  • Sunil A. Patel · Executive Officer
  • Timothy J. Hoey · Executive Officer
  • William D. Waddill · Executive Officer
  • Deepa J. Pakianathan · Director
  • Denise J. Pollard-Knight · Director
  • Jack J. Lasersohn · Director
  • James J. Broderick · Director
  • Jim J. Woody · Director
  • Jonathan J. Root · Director
  • Larry J. Lasky · Director
  • Michael J. Wyzga · Director
  • Terry J. Gould · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William D. Waddill, Sr. VP and CFO. Source: SEC Form D, newest notice filed Dec 6, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • OncoMed Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Dec 2013).

    SEC Form D · Dec 2013

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2013

That is all the official record says: OncoMed Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of OncoMed Pharmaceuticals Inc are on record.

Investors#

21 named in official filings. Open an investor to see everything it has backed.

Investors in OncoMed Pharmaceuticals Inc
InvestorKindAmountRoundRoleSource
Austin GurneyPersonnot statednot statedHeld Series B and B-1 preferred stock (Form 3, 2013)SEC Form 3
GSK PLCFund or asset managernot statednot statedHeld Series B-2 and B-3 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
John A. LewickiPersonnot statednot statedHeld Series B and B-1 preferred stock (Form 3, 2013)SEC Form 3
LVP GP III, LLCOthernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
LVP GP II, LLCOthernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
LVP GP I, LLCOthernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
LVP III Associates, L.P.Fund or asset managernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
LVP III Partners LPFund or asset managernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
LVP Life Science Ventures III L.P.Venture capitalnot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
LVP Life Science Ventures II, L.P.Venture capitalnot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
LVP Life Science Ventures I, L.P.Venture capitalnot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Lvpmc, LLCOthernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Morgenthaler Management Partners VII, LLCFund or asset managernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Morgenthaler Partners VII LPFund or asset managernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Presidio Management Group VIII L L CFund or asset managernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Timothy HoeyPersonnot statednot statedHeld Series B and B-1 preferred stock (Form 3, 2013)SEC Form 3
US Venture Partners VIII L.P.Venture capitalnot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Usvp Entrepreneur Partners VIII A L.P.Fund or asset managernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Usvp Entrepreneur Partners VIII B L.P.Fund or asset managernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Usvp VIII Affiliates Fund L.P.Fund or asset managernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Vertical Group LPFund or asset managernot statednot statedHeld Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by OncoMed Pharmaceuticals Inc
NameRoleNamed in
Alicia J. HagerExecutive officerDec 2013
Austin J. GurneyExecutive officerDec 2013
Jakob A. DupontExecutive officerDec 2013
John A. LewickiExecutive officerDec 2013
Paul J. HastingsExecutive officerDec 2013
Sunil A. PatelExecutive officerDec 2013
Timothy J. HoeyExecutive officerDec 2013
William D. WaddillExecutive officerDec 2013
Deepa J. PakianathanDirectorDec 2013
Denise J. Pollard-KnightDirectorDec 2013
Jack J. LasersohnDirectorDec 2013
James J. BroderickDirectorDec 2013
Jim J. WoodyDirectorDec 2013
Jonathan J. RootDirectorDec 2013
Larry J. LaskyDirectorDec 2013
Michael J. WyzgaDirectorDec 2013
Paul J. HastingsDirectorDec 2013
Terry J. GouldDirectorDec 2013

About

Public American pharmaceutical company.